• Busca persones
• Intranet

Neurofarmacologia Rafael Maldonado

Publicacions 2024 (5)

• Samulenaite S, García-Blanco A, Mayneris-Perxachs J, Domingo L, Cabana-Domínguez J, Fernández-Castillo N, Gago-García E, Pineda-Cirera L, Burokas A, Espinosa JA, Arboleya S, Latorre J, Stanton C, Hosomi K, Kunisawa J, Cormand B, Fernández-Real JM, Maldonado R^*, Martín-García E. Gut microbiota signatures of vulnerability to food addiction in mice and humans. Gut 2024: (en Premsa).
• Favier M^*, Martín-García E, Icick R, de Almeida C, Jehl J, Desplanque M, Zimmermann J, Henrion A, Mansouri-Guilani N, Mounier C, Ribeiro S, Henderson F, Geoffroy A, Mella S, Poirel O, Bernard V, Fabre V, Li Y, Rosenmund C, Jamain S, Vorspan F, Mourot A, Duriez P, Pinhas L, Maldonado R, Pietrancosta N, Daumas S, El Mestikawy S^*. The human VGLUT3-pT8I mutation elicits uneven striatal DA signaling, food or drug maladaptive consumption in male mice. Nat Commun 2024; 15(1): 5691.
• Cárdenas-Quesada J, Mestre J, Maldonado R, de Fonseca FR, Torrens M, Farré M^*, on behalf the RIAPAd research group. Substance use disorders and cooperative research on addictions: Spanish approach as a model. Pharmacol Res 2024; 206: 107233.
• Bergada A. Cognitive and synaptic outcomes of targeting peripheral cannabinoid type-1 receptor: focus on naïve and intellectual disability mouse models. Universitat Pompeu Fabra. Director: Ozaita A, Maldonado R. Fecha lectura: 03/04/2024.
  Cites:0
• Grau S, Vela JM, Gurt A, Barceló-Vidal J, Ojeda FA, Lopez I, Gómez-García L, Loza MI, Martín-García E, Maldonado R^*, Monfort J, SIGMA Group. Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients. J. Infect. 2024; 88(2): 187-190.